Insider · CIK 0001340881
Kimberlee C Drapkin
director
Files at KANT (KINETA, INC./DE), ABOS (Acumen Pharmaceuticals, Inc.), CLYM (Climb Bio, Inc.), LENZ (LENZ Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 23, 2025 | KANT KINETA, INC./DE | MOption exercise Common Stock | +12,500 | $0.61 | $7,638 | 12,500 | Jun 25, 2025 |
| Jun 23, 2025 | KANT KINETA, INC./DE | FTax withholding Common Stock | -4,706 | $0.26 | $1,224 | 7,794 | Jun 25, 2025 |
| Jun 25, 2025 | KANT KINETA, INC./DE | AGrant or award Common Stock | +6,000 | $0.00 | $0 | 13,794 | Jun 25, 2025 |
| Jun 23, 2025 | KANT KINETA, INC./DE | MOption exercise Stock Option (Right to Buy)derivative | -12,500 | $0.00 | $0 | 0 | Jun 25, 2025 |
| Jun 11, 2025 | LENZ LENZ Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +13,500 | $0.00 | $0 | 13,500 | Jun 11, 2025 |
| Jun 4, 2025 | ABOS Acumen Pharmaceuticals, Inc. | AGrant or award Common Stock | +12,800 | $0.00 | $0 | 12,800 | Jun 5, 2025 |
| Jun 4, 2025 | CLYM Climb Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jun 5, 2025 |
| Jun 4, 2025 | ABOS Acumen Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +19,500 | $0.00 | $0 | 19,500 | Jun 5, 2025 |
| Mar 28, 2025 | CLYM Climb Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Apr 1, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.